Combiwave 25/125 µg is a fixed-dose combination prescription inhaler indicated for the regular maintenance treatment of reversible obstructive airway diseases, including asthma and chronic obstructive pulmonary disease (COPD).
Delivering a fixed ratio of a long-acting beta2-adrenergic agonist (LABA) and an inhaled corticosteroid (ICS), Combiwave helps manage chronic respiratory symptoms, prevent bronchospasm, and reduce airway inflammation.
Clinical Note: Combiwave is formulated specifically for daily prophylactic maintenance. It is not indicated for the immediate relief of acute asthma attacks or sudden bronchospasms, which require a fast-acting short-acting beta2-agonist (SABA) rescue inhaler.
Active Ingredients & Dual-Mechanism Profile
Each metered actuation (puff) of Combiwave delivers two complementary active pharmaceutical ingredients:
Salmeterol (25 µg as Xinafoate): A selective long-acting beta2-adrenergic receptor agonist (LABA). Salmeterol works by stimulating beta2-receptors in bronchial smooth muscle, inducing relaxation and long-term bronchodilation that lasts for approximately 12 hours.
Fluticasone Propionate (125 µg): A potent synthetic corticosteroid with strong anti-inflammatory action. It suppresses mucosal inflammation, decreases airway hyperresponsiveness, and reduces vascular permeability and mucus hypersecretion in the lungs.
Synergistic Physiological Action
Bronchodilation: Salmeterol acts locally to keep airways open and clear, facilitating smoother airflow and easing exertion during breathing.
Anti-Inflammatory Suppression: Fluticasone propionate targets the underlying cellular pathways of airway inflammation, reducing swelling and mucosal irritation.
Combined Maintenance Efficacy: Together, the two agents address both the mechanical contraction and the underlying inflammatory process of airway disorders, leading to improved pulmonary function and fewer disease exacerbations over time.
Key Medical Indications & Clinical Benefits
Long-Term Asthma Management: Recommended for patients whose asthma is insufficiently controlled with an inhaled corticosteroid alone or for those whose condition is well stabilized on combined ICS and LABA therapy.
COPD Maintenance Therapy: Indicated for the symptomatic management of patients with severe COPD who experience frequent exacerbations despite regular bronchodilator treatment.
Reduction of Exacerbations: Regular daily administration decreases the frequency and severity of asthma attacks and chronic pulmonary flare-ups.
Improved Lung Function: Sustained dual action leads to improved forced expiratory volume (FEV1) and peak expiratory flow (PEF) rates.
Usage Instructions & Dosage Protocol
Combiwave must be taken regularly every day, even when patients are asymptomatic, to maintain optimal control over airway inflammation.
Standard Adult & Adolescent Dosage (12 Years and Older): The usual recommended dosage is two inhalations twice daily (morning and evening), approximately 12 hours apart, or as prescribed by a healthcare professional.
Administration Procedure:
Remove the mouthpiece cover and check for clean condition.
Shake the inhaler thoroughly before each actuation.
Exhale fully away from the inhaler.
Place the mouthpiece tightly between the lips, inhale deeply and steadily through the mouth while pressing down firmly on the canister to release a dose.
Hold breath for 5 to 10 seconds (or as long as comfortable) before exhaling slowly.
Post-Inhalation Care: Always rinse the mouth thoroughly with water and spit it out (do not swallow) after taking a dose to reduce the risk of oral fungal infections (thrush) and hoarseness.
Safety Precautions, Warnings & Contraindications
Absolute Contraindications
Severe Hypersensitivity: Known hypersensitivity to Salmeterol Xinafoate, Fluticasone Propionate, or any of the propellant excipients.
Monotherapy in Acute Exacerbations: Must not be initiated during acute, severe asthma exacerbations or life-threatening episodes of sudden onset shortness of breath.
Clinical Warnings & Precautions
Oropharyngeal Candidiasis & Dysphonia: Inhaled corticosteroids increase the incidence of localized fungal infections (oral thrush) and voice changes. Routine post-dose oral rinsing mitigates this risk significantly.
Paradoxical Bronchospasm: As with other inhalation therapies, sudden bronchospasm may occur immediately after dosing. If this occurs, treat immediately with a short-acting rescue bronchodilator, discontinue Combiwave, and seek medical evaluation.
Systemic Corticosteroid Effects: High doses administered over extended periods may lead to systemic corticosteroid absorption. Monitoring for decreased bone mineral density, elevated intraocular pressure (glaucoma), cataracts, and adrenal suppression is advisable during long-term therapy.
Cardiovascular Monitoring: Beta2-agonists can produce significant cardiovascular effects in some patients, including increased pulse rate, elevated blood pressure, and cardiac arrhythmias. Use with caution in patients with pre-existing cardiovascular disorders or thyrotoxicosis.
Product Specifications & Storage Conditions
Dosage Form: Pressurised metered-dose inhalation suspension.
Package Content: 1 Canister delivering 120 metered doses (actuations).
Storage Requirements: Store below 30°C in a dry place. Protect from direct heat, sunlight, and freezing temperatures. Do not puncture or incinerate the pressurized container even when empty. Keep out of reach of children.
Medication
